Market
How will Duvakitug's market share change within a year after Phase 3 results?
2
Resolution / Starting Odds
Increase by >10% • 25%
Increase by 5-10% • 25%
Increase by <5% • 25%
No significant change • 25%
Market analysis reports from firms like IMS Health or EvaluatePharma
Story
Teva and Sanofi's Duvakitug Shows Promise in Phase 2b Trial for IBD, Shares Surge
Dec 17, 2024, 03:45 PM
Teva Pharmaceutical Industries and Sanofi have announced positive results from a Phase 2b clinical trial named RELIEVE UCCD for their drug, Duvakitug, which targets ulcerative colitis and Crohn's disease. The trial showed that Duvakitug met its primary endpoints, with 36.2% of ulcerative colitis patients on a low dose and 47.8% on a high dose achieving clinical remission, compared to 20.45% on placebo. For Crohn's disease, 26.1% of patients on a low dose and 47.8% on a high dose achieved an endoscopic response, compared to 13% on placebo. The drug was well tolerated with no safety signals identified. Following these results, Teva's shares surged by nearly 20%, while Sanofi's shares climbed by almost 5%. The companies plan to initiate Phase 3 development pending regulatory discussions.
View original story
Similar markets
Less than 10% • 25%
20% to 30% • 25%
More than 30% • 25%
10% to 20% • 25%
More than 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
20% to 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
More than 30% • 25%
Negative results • 33%
Positive results • 33%
Inconclusive results • 34%
25% to 50% • 25%
More than 75% • 25%
50% to 75% • 25%
Less than 25% • 25%
Less than 5% • 25%
More than 20% • 25%
10% to 20% • 25%
5% to 10% • 25%
More than 60% • 25%
41% to 60% • 25%
20% to 40% • 25%
Less than 20% • 25%
Remains within 10% of current share • 25%
Decreases by more than 10% • 25%
Increases by more than 10% • 25%
Other • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
More than 50% • 25%
30% to 50% • 25%
10% to 30% • 25%
Less than 10% • 25%
Yes • 50%
No • 50%
